Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 63

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 63
---
 to measure dissolved tissue oxygen for up to six months following sensor injection. Initial product uses under development include application for the management of wound care for critical limb ischemia (a condition involving blockage in the arteries of the lower extremities, markedly reducing blood flow) patients in surgical settings, followed by use in ambulatory settings, subject to future regulatory approval. Lumee Glucose is an investigational product development system, as Profusa has yet to receive the regulatory approval necessary for commercialization in any jurisdiction. It is being developed for use to monitor optical signals that represent glucose levels in the interstitial (under and between the skin and blood vessels) fluid of subcutaneous tissue continuously and long -term. The Business Combination The Merger Agreement On November 7, 2022, NorthView, Profusa, and Merger Sub, entered into the Merger Agreement, which contains customary representations and warranties, covenants, closing conditions, termination provisions and other terms relating to the Business Combination and the other transactions contemplated thereby, as summarized below. Capitalized terms used in this section but not otherwise defined herein have the meanings given to them in the Merger Agreement. The Structure of the Business Combination Pursuant to the Merger Agreement, on the Closing Date, at the Effective Time, Merger Sub will merge with and into Profusa, with Profusa as the surviving company in the Merger and, after giving effect to such Merger, Profusa shall be a wholly owned subsidiary of NorthView. In connection with the Merger, NorthView will change its name to “Profusa, Inc.” For more information, see the section entitled “ The Merger Agreement — The Structure of the Business Combination.” Consideration to Be Received in the Business Combination Following the entry into Amendment No. 4 to the Merger Agreement (as defined above), the aggregate consideration to be received by the Profusa shareholders is based on the sum of (a) the pre -transactionequity value of $155,000,000, plus (b) the Incentive Equity Value (which is expected to be $29,018,330 for purposes of this proxy statement/prospectus), plus (c) the Private Placement Value (which is expected to be $14,867,899 for purposes of this proxy statement/prospectus), plus (d) the Aggregate Exercise Price, minus (e) the Aggregate Company Incentive Amount. In accordance with the terms and subject to the conditions of the Merger Agreement, immediately prior to the Effective Time,